Wells Fargo & Company Nuvation Bio Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NUVB
# of Institutions
154Shares Held
124MCall Options Held
9.7KPut Options Held
6.5K-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$50.3 Million1.98% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$42.5 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.3MShares$34.8 Million50.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$26.6 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA6.95MShares$18.2 Million6.22% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $569M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...